4 completed, 1 recruiting. 3 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Best Available Treatment: new trials by email Literature Review of Best Available Treatment trials Research Report on Best Available Treatment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia INCA033989, Best Available Treatment - Essential Thrombocythemia | Phase 3 | Recruiting | Incyte Corporation | 426 | 2026-09-08 | 2026-10-15 |
| Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors asciminib, best available treatment - Leukemia, Chronic Myelogenous | Phase 2 | Completed | Novartis Pharmaceuticals | 84 | 2021-12-06 | 2025-04-18 |
| Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults Zavicefta, Ceftazidime-Avibactam, Best Available Treatment - Urinary Tract Infection, Acute Pyelonephritis | Phase 4 | Completed | Pfizer | 60 | 2021-08-26 | 2024-10-21 |
| Clinical Trial of Sarilumab in Adults With COVID-19 Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA], Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA], Best available treatment - SARS-CoV 2, SARS | Phase 2 | Completed | Maimónides Biomedical Research Institute of Córdoba | 120 | 2020-04-28 | 2021-07-07 |
| Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19 Antithrombin + best available treatment, Best available treatment - Covid19, Severe Acute Respiratory Syndrome | Phase 2 | Completed | Maimónides Biomedical Research Institute of Córdoba | 48 | 2020-04-27 | 2021-02-09 |
Bacteremia (1) · Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · Healthcare-Associated Pneumonia (1) · Intraabdominal Infections (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Pneumonia, Ventilator-Associated (1) · Pulmonary Atelectasis (1) · Severe Acute Respiratory Syndrome (1) · Thrombocythemia, Essential (1) · Urinary Tract Infections (1)
Maimónides Biomedical Research Institute of Córdoba (2) · Incyte Corporation (1) · Novartis Pharmaceuticals (1) · Pfizer (1)
Spain (3) · China (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Netherlands (1) · Norway (1) · Poland (1)